中基長壽科學(00767.HK)成立合資公司 擬從事生物醫藥產品貿易
中基長壽科學(00767.HK)公布,於昨日(26日),其全資附屬公司深圳市中基健康科學與成都冠德堂生物科技訂立合資協議,以在中國成立一間合資公司。
合資公司於成立時,將由中基健康擁有51%及冠德堂擁有49%股權。合資公司將主要從事在中國提供生物醫藥產品貿易的業務。
合資公司的初始註冊資本為300萬元人民幣,將由中基健康及冠德堂按各自的權益比例出資。出資款將主要用作合資公司的營運資金。該公司將以內部資源為其資本承擔提供資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.